DK0662130T3 - Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje - Google Patents
Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinjeInfo
- Publication number
- DK0662130T3 DK0662130T3 DK93921471T DK93921471T DK0662130T3 DK 0662130 T3 DK0662130 T3 DK 0662130T3 DK 93921471 T DK93921471 T DK 93921471T DK 93921471 T DK93921471 T DK 93921471T DK 0662130 T3 DK0662130 T3 DK 0662130T3
- Authority
- DK
- Denmark
- Prior art keywords
- met
- hgf
- preparation
- antibody
- substance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94606192A | 1992-09-18 | 1992-09-18 | |
PCT/US1993/008531 WO1994006909A2 (en) | 1992-09-18 | 1993-09-15 | A method of preventing tumor metastasis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0662130T3 true DK0662130T3 (da) | 1998-08-10 |
Family
ID=25483898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93921471T DK0662130T3 (da) | 1992-09-18 | 1993-09-15 | Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0805203B1 (da) |
JP (2) | JP3553936B2 (da) |
AT (2) | ATE160585T1 (da) |
AU (1) | AU675968B2 (da) |
CA (1) | CA2144856A1 (da) |
DE (2) | DE69315440T2 (da) |
DK (1) | DK0662130T3 (da) |
ES (1) | ES2112997T3 (da) |
GR (1) | GR3026165T3 (da) |
WO (1) | WO1994006909A2 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US6566098B1 (en) | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
CA2144081C (en) * | 1992-09-16 | 2004-11-30 | Filip Roos | Protection against liver damage by hgf |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
US6855685B2 (en) | 1995-10-24 | 2005-02-15 | Toshikazu Nakamura | Anti-cancer agent |
JP3832674B2 (ja) * | 1995-10-24 | 2006-10-11 | 敏一 中村 | 抗癌剤 |
EP0941111A4 (en) * | 1996-11-05 | 2000-09-27 | Smithkline Beecham Corp | HEPATOCYTE GROWTH FACTOR ANTAGONISTS |
AU1465400A (en) * | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay |
IL131142A0 (en) * | 1999-07-28 | 2001-01-28 | Rad Ramot | Prognosis of breast cancer and other diseases |
AU1598801A (en) * | 1999-11-09 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | HGF-SF monoclonal antibody combinations |
AU2001277854B2 (en) * | 2000-06-29 | 2007-03-01 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
RS53476B (en) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
AU2005267720B2 (en) | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
ES2440953T3 (es) | 2005-03-31 | 2014-01-31 | The General Hospital Corporation | Modulación de la actividad de HGF/HGFR para tratar un linfedema |
SG161281A1 (en) | 2005-04-15 | 2010-05-27 | Genentech Inc | Hgf beta chain variants |
CA2646620C (en) * | 2006-03-20 | 2015-07-14 | Seikagaku Corporation | Therapeutic agent for rheumatoid arthritis |
EP2004693B1 (en) | 2006-03-30 | 2012-06-06 | Novartis AG | Compositions and methods of use for antibodies of c-met |
AU2011226103C1 (en) | 2010-03-10 | 2016-04-28 | Genmab A/S | Monoclonal antibodies against c-Met |
US8637027B2 (en) | 2010-11-03 | 2014-01-28 | Argen-X B.V. | Anti c-Met antibodies |
EP2709650B1 (en) * | 2011-04-02 | 2017-02-08 | Washington State University | Hepatocyte growth factor mimics as therapeutic agents |
US20130004484A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
US5648273A (en) * | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
GB9003621D0 (en) * | 1990-02-16 | 1990-04-11 | Imp Cancer Res Tech | Protein factor |
JP2784455B2 (ja) * | 1990-05-09 | 1998-08-06 | 敏一 中村 | 肝硬変治療剤 |
ATE256736T1 (de) * | 1990-09-14 | 2004-01-15 | Us Health | Ein nicht-mitogener kompetitiver hgf-antagonist |
EP0642580B1 (en) * | 1992-05-18 | 2002-08-21 | Genentech, Inc. | Hepatocyte growth factor variants |
-
1993
- 1993-09-15 EP EP97201105A patent/EP0805203B1/en not_active Expired - Lifetime
- 1993-09-15 DE DE69315440T patent/DE69315440T2/de not_active Expired - Fee Related
- 1993-09-15 AT AT93921471T patent/ATE160585T1/de not_active IP Right Cessation
- 1993-09-15 EP EP93921471A patent/EP0662130B1/en not_active Expired - Lifetime
- 1993-09-15 AU AU48555/93A patent/AU675968B2/en not_active Ceased
- 1993-09-15 JP JP50817794A patent/JP3553936B2/ja not_active Expired - Fee Related
- 1993-09-15 WO PCT/US1993/008531 patent/WO1994006909A2/en active IP Right Grant
- 1993-09-15 DE DE69334159T patent/DE69334159D1/de not_active Expired - Lifetime
- 1993-09-15 AT AT97201105T patent/ATE368738T1/de not_active IP Right Cessation
- 1993-09-15 CA CA002144856A patent/CA2144856A1/en not_active Abandoned
- 1993-09-15 ES ES93921471T patent/ES2112997T3/es not_active Expired - Lifetime
- 1993-09-15 DK DK93921471T patent/DK0662130T3/da active
-
1998
- 1998-02-18 GR GR980400340T patent/GR3026165T3/el unknown
-
2003
- 2003-06-10 JP JP2003165273A patent/JP2004002440A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE368738T1 (de) | 2007-08-15 |
ES2112997T3 (es) | 1998-04-16 |
JPH08504093A (ja) | 1996-05-07 |
DE69315440D1 (de) | 1998-01-08 |
EP0805203A1 (en) | 1997-11-05 |
JP2004002440A (ja) | 2004-01-08 |
EP0662130A1 (en) | 1995-07-12 |
EP0662130B1 (en) | 1997-11-26 |
AU4855593A (en) | 1994-04-12 |
WO1994006909A2 (en) | 1994-03-31 |
GR3026165T3 (en) | 1998-05-29 |
EP0805203B1 (en) | 2007-08-01 |
DE69334159D1 (de) | 2007-09-13 |
CA2144856A1 (en) | 1994-03-31 |
ATE160585T1 (de) | 1997-12-15 |
JP3553936B2 (ja) | 2004-08-11 |
DE69315440T2 (de) | 1998-07-09 |
WO1994006909A3 (en) | 1994-05-26 |
AU675968B2 (en) | 1997-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0662130T3 (da) | Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje | |
DE69433406D1 (de) | Antikörper gegen cd40 | |
NO2017038I1 (no) | Adalimumab - Forlenget SPC | |
UA111707C2 (uk) | Застосування виділеного анти-tnf-альфа антитіла людини | |
MY145191A (en) | Human antibodies that bind human il-12 and methods for producing | |
DE69233482D1 (de) | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen | |
ATE162079T1 (de) | Verwendung von antikörper enthaltenden präparationen zur immunsuppression | |
DE69328928D1 (de) | Varianten in den leltin domäne von selektin | |
BR0314369A (pt) | Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado | |
DK0504307T3 (da) | Fremgangsmåde til behandling af septisk shock | |
DK361282A (da) | Fremgangsmaade til fremstilling af o-alkyl-o-carbamoylglycerophosphocholiner | |
DE69527868D1 (de) | Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II) | |
DE60020729D1 (de) | Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen | |
DK119891D0 (da) | Forbedringer ved og i forbindelse med magnetisk resonansafbildning | |
DE69112392T2 (de) | Bcrf1-antagonisten zur behandlung von epstein-barr-virus-infektionen. | |
EP0420102A3 (en) | Stabilization of monoclonal antibody for use in fluorescent polarization techniques | |
KR960028933U (ko) | 자화수 제조용 물통 속마개 | |
Durand-Charre et al. | Structure and Solidification Sequence of Alloyed White Cast Irons.(Synopsis) | |
DK159280A (da) | Fremgangsmaade til styring af kontrasten ved reproduktion saasom rasterreproduktion | |
ES2030342A6 (es) | Procedimiento de obtencion de una fuente de antigeno para el serodiagnostico inmunohistologico de la listerioris. | |
Gurjevitch | Rasryschitelnoe b tscheloveke kak tajny | |
DK26393D0 (da) | Fremgangsmaade til overfladebehandling af isaer graat staabejern |